- Home
- BTAI vs VNRX Comparison
BTAI vs VNRX Comparison
Compare BTAI & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BTAI | VNRX |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.7M | 35.0M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | BTAI | VNRX |
|---|---|---|
| Price | $1.62 | $0.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $26.67 | $2.50 |
| AVG Volume (30 Days) | 494.6K | ★ 2.1M |
| Earning Date | 03-26-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $752,000.00 | ★ $1,472,007.00 |
| Revenue This Year | N/A | $55.98 |
| Revenue Next Year | $265.60 | $420.37 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 14.48 |
| 52 Week Low | $1.17 | $0.22 |
| 52 Week High | $8.08 | $0.94 |
Technical Indicators
Market Signals| Indicator | BTAI | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.02 | 36.48 |
| Support Level | $1.36 | $0.24 |
| Resistance Level | $1.72 | $0.28 |
| Average True Range (ATR) | 0.12 | 0.02 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 45.10 | 5.64 |
Price Performance
Historical ComparisonAbout BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About VNRX VolitionRX Limited
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.